Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of Kangai No.2 prescription on immune system of patients with advanced colorectal cancer: a randomized controlled study

ABSTRACT: Interventions: experimental group:Kangai No.2 prescription;control group:placebo Primary outcome(s): Tumor recurrence rate;survival rate Study Design: Parallel

DISEASE(S): Colorectal Cancer

PROVIDER: 2696665 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

A Randomized Controlled Trial of Advanced Colorectal Cancer with Fuzheng Jiedu Prescription Combined with Chemotherapy

Project description:Interventions: Experimental group:Fuzheng Jiedu Prescription Combined with Chemotherapy;control group:Chemotherapy Primary outcome(s): PFS Study Design: Parallel

| 2699171 | ecrin-mdr-crc

Clinical study on the prevention and treatment of colorectal adenoma by regulating intestinal microecology: a randomized double-blind controlled trial

Project description:Interventions: experimental group 1:Yiyi Fuzi Baijiang Powder;experimental group 2:Sanwu Huangqin Decoction;placebo group 1:Yiyi Fuzi Baijiang Powder placebo agent;placebo group 2:Sanwu Huangqin Decoction placebo agent Primary outcome(s): recurrence rate Study Design: Parallel

| 2693768 | ecrin-mdr-crc

Double-blinded Randomized Controlled Trial for Qu-Xie Capsule Regulating Gut Micro-biome and Body Immune System in Patients with Advanced Colorectal Cancer

Project description:Interventions: Experimental group:Quxie capsule;Control group:Placebo Primary outcome(s): OS Study Design: Parallel

| 2690311 | ecrin-mdr-crc

Clinical study on the prevention of postoperative recurrence and metastasis of colorectal cancer by Zuojin pill combined with adjuvant chemotherapy

Project description:Interventions: experimental group:Zuojin Pill; placebo group:Zuojin Pill placebo Primary outcome(s): recurrence rate Study Design: Parallel

| 2693767 | ecrin-mdr-crc

Study for blood metabolomics of patients after laparoscopic colorectal cancer surgery with Xiangbin prescription

Project description:Interventions: Group 1:Routine therapy plus Xiangbin prescription for patients with colorectal cancer (preoperative + postoperative);Group 2:Routine therapy plus placebo for patients with colorectal cancer (preoperative + postoperative);Healthy person:No Intervention Primary outcome(s): Small Molecular Metabolomics of Blood Study Design: Non randomized control

| 2682122 | ecrin-mdr-crc

A clinical study on the Regulation of Intestinal Microenvironment in coIX Lachana Fujiang Powder for the prevention and Treatment of malignant neoplasia in advanced colorectal adenoma

Project description:Interventions: Experimental group:Yiyi Fuzi Baijiang Powder; placebo group:Yiyi Fuzi Baijiang Powder placebo Primary outcome(s): recurrence rate Study Design: Parallel

| 2697293 | ecrin-mdr-crc

Clinical research for San-Wu-Huang-Qin decoction in the prevention and treatment of recurrence of colorectal adenoma

Project description:Interventions: Experimental group:Sanwu Huangqin decoction;control group:placebo Primary outcome(s): Recurrence rate of adenoma Study Design: Parallel

| 2692741 | ecrin-mdr-crc

Molecular classification of the placebo effect in nausea by mass spectrometry

Project description:In this proof-of-concept study, we tested whether placebo effects can be monitored and predicted by plasma proteins. In a randomized controlled design, 90 participants were exposed to a nauseating stimulus on two separate days and were randomly allocated to placebo treatment or no treatment on the second day. Significant placebo effects on nausea, motion sickness, and gastric activity could be verified. Using state-of-the-art proteomics, 74 differentially regulated proteins were identified as correlates of the placebo effect. Gene ontology (GO) enrichment analyses identified acute-phase proteins and microinflammatory proteins to be involved, and the identified GO signatures predicted day-adjusted scores of nausea indices in the placebo group. We also performed GO enrichment analyses of specific plasma proteins predictable by the experimental factors or their interactions and identified ‘grooming behavior’ as a prominent hit. Finally, Receiver Operator Characteristics allowed to identify plasma proteins differentiating placebo responders from non-responders, comprising immunoglobulins and proteins involved in oxidation reduction processes and complement activation. Plasma proteomics are a promising tool to identify molecular correlates and predictors of the placebo effect in humans.

2020-11-13 | PXD020563 | Pride

Effects of Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032 on Overweight and Gut Microbiota in Human: Randomized, Double-Blinded, Placebo-Controlled Clinical Trial

Project description:Obesity and overweight are closely related to diet, and gut microbiota play an important role in body weight and human health. The aim of this study was to explore how Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032 supplementation alleviate obesity by modulating the human gut microbiome. A randomized, double-blind, placebo-controlled study was conducted on 72 overweight individuals. Over a 12-week period, probiotic groups consumed 5×10^9 colony-forming units of HY7601 and KY1032), whereas the placebo group consumed the same product without probiotics. After treatment, the probiotic group displayed a reduction in body weight (p <0.001), visceral fat mass (p <0.025), and waist circumference (p <0.007), and an increase in adiponectin (p <0.046), compared with the placebo group. Additionally, HY7601 and KY1032 supplementation modulated bacterial gut microbiota characteristics and beta diversity by increasing Bifidobacteriaceae and Akkermansiaceae, and decreasing Prevotellaceae and Selenomonadaceae. In summary, HY7601 and KY1032 probiotics exert anti-obesity effects by regulating the gut microbiota; hence, they have therapeutic potential for preventing or alleviating obesity and overweight.

2022-05-12 | GSE202489 | GEO

Study of standard formulation of postoperative gastrointestinal motility

Project description:Interventions: Xiangbin prescription group:Xiangbin prescription plus basic therapies;placebo group:placebo plus basic therapies;blank control group:basic therapies;Shenbin prescription:Shenbin prescription plus basic therapies;blank control group:basic therapies Primary outcome(s): gastrointstinal hormon;gastrointestianl manometry indicators;electrogastrogram Study Design: Randomized parallel controlled trial

| 2667145 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data